Sign in
VIRX Stock Price, Chart, Stats & News
Viracta Therapeutics, Inc.
Save
Viracta Therapeutics, Inc. (VIRX) does not currently pay a dividend.
388,698
Market cap
–
Current P/E
–
Forward P/E
VIRX chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Viracta Therapeutics, Inc. operates as a precision oncology firm, specializing in the development of therapeutic agents aimed at treating cancers linked to viral infections. The company's leading drug candidate, Nana-val (a combination of nanatinostat and valganciclovir), is currently advancing through multiple clinical trials. It is in Phase II development for Epstein-Barr virus-positive (EBV+) lymphoma.
Similar securities
Based on sector and market capitalization
Report issue